RENB 1.42 ▲ 0.00% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Lunai Bioworks Inc.

    NASDAQ: RENB · Real-Time Price · USD
    1.42
    0.00 (0.00%)
    At close: Jun 09, 2025, 3:59 PM
    0.00%
    Bid 1.42
    Market Cap 32.91M
    Revenue (ttm) 181.45K
    Net Income (ttm) -67.01M
    EPS (ttm) -2.43
    PE Ratio (ttm) -0.58
    Forward PE n/a
    Analyst n/a
    Dividends n/a
    Ask 1.54
    Volume 808,780
    Avg. Volume (20D) 205,813
    Open 1.19
    Previous Close 1.42
    Day's Range 1.19 - 1.42
    52-Week Range 1.13 - 21.00
    Beta 0.53
    Ex-Dividend Date n/a

    About RENB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol RENB
    Website n/a
    Full Company Profile
    6 days ago
    -18.5%
    Lunai Bioworks shares are trading lower . The comp... Unlock content with Pro Subscription
    1 month ago
    +12.17%
    Renovaro shares are trading higher. The company announced it will change its corporate name to Lunai Bioworks Inc.
    news image

    5 days ago · accessnewswire.com

    Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

    NEW YORK CITY, NEW YORK / ACCESS Newswire / September 25, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery company and parent of wholly owned subsidiary BioSymetrics, today annou...

    news image

    1 week ago · accessnewswire.com

    Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

    Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price LOS ANGELES, CA / ACCESS Newswire / September 24, 2025 / Lunai Bioworks, Inc. (Nasdaq:RENB) ("Lunai Bioworks" or the "Co...

    news image

    2 weeks ago · accessnewswire.com

    Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

    BETHESDA, MD / ACCESS Newswire / September 11, 2025 / Lunai Bioworks Inc.'s (NASDAQ:RENB) wholly-owned subsidiary BioSymetrics Inc. today announced the award of a prestigious Small Business Technology...

    news image

    3 weeks ago · benzinga.com

    Top 3 Health Care Stocks You'll Regret Missing In Q3

    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

    news image

    3 weeks ago · accessnewswire.com

    Lunai Bioworks Strengthens European Strategy Through Restructuring

    Company remains committed to Europe with a streamlined, growth-focused approach. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Lunai Bioworks Inc. (Nasdaq:RENB), an AI-powered drug d...

    news image

    3 weeks ago · accessnewswire.com

    Lunai Bioworks Inc. Retains American Defense International

    Collaboration aims to apply Lunai Bioworks Inc. biomedical AI platform to accelerate countermeasure development for chemical agents like sarin and other biothreats LOS ANGELES, CALIFORNIA / ACCESS New...

    news image

    1 month ago · accessnewswire.com

    Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

    LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical W...

    news image

    2 months ago · accessnewswire.com

    Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

    Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2...

    news image

    2 months ago · accessnewswire.com

    Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

    Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro...

    news image

    2 months ago · accessnewswire.com

    Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

    LOS ANGELES, CA / ACCESS Newswire / July 9, 2025 / Renovaro Inc. (NASDAQ:RENB), an AI-driven precision medicine company, today announced that senior debt holders have agreed to convert an aggregate of...

    Add to Watchlist